OncoMatch/Clinical Trials/NCT06771219
SLV-154 Treatment of Metastatic Solid Tumors
Is NCT06771219 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SLV-154 for squamous cell cancer of head and neck (scchn).
Treatment: SLV-154 — This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Cervical Cancer
Breast Carcinoma
Endometrial Cancer
Ovarian Cancer
Urothelial Carcinoma
Sarcoma
Thyroid Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: commercially available therapies indicated for the subject's cancer and have demonstrated survival benefit
Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication
Lab requirements
Blood counts
adequate hematological profile
Kidney function
adequate renal function
Liver function
adequate hepatic profile
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Washington University · St Louis, Missouri
- Astera Cancer Care · East Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify